Spyre Therapeutics, Inc. (SYRE) Institutional Ownership

Ownership Summary

Spyre Therapeutics, Inc. (NASDAQ:SYRE) has 151 institutional investors with active 13F positions as of December 2025.

• They owned 131.2% of outstanding stock in December 2025, up from 107.5% the prior quarter.
• Their total shares held in SYRE increased 27.82% from the prior quarter, while the number of investors in Spyre Therapeutics increased 16.15% year over year.
• During the quarter, 104 of these 151 funds increased positions in SYRE, 27 reduced exposure, and 20 held steady.
• Combined, these investors held 79.28Mn shares in SYRE for December 2025, up by 17.26Mn shares quarter on quarter, and up 17.86Mn shares year over year.
• As of December 31, 2025, FMR LLC held the largest stake in Spyre Therapeutics with 11.78Mn shares, accounting for 19.5% of total shares outstanding.
• The most significant purchases of SYRE for the quarter ending December 2025 came from VANGUARD CAPITAL MANAGEMENT LLC (3.06Mn), PRICE T ROWE ASSOCIATES INC /MD/ (1.6Mn), Janus Henderson Group Plc (1.48Mn), Jpmorgan Chase & Co (916.35K), Caligan Partners LP (878.13K).
• Top sellers of SYRE stock for the quarter ending December 2025 included Capital International Investors (1.75Mn), BRAIDWELL LP (701.79K), Commodore Capital LP (475.86K), Pictet Asset Management Holding SA (422.31K), Goldman Sachs Group Inc (280.19K).
• According to Business Quant data, leading holders of SYRE for December 2025 are FMR LLC (11.78Mn), BlackRock, Inc. (5.52Mn), RTW INVESTMENTS, LP (4.17Mn), Fairmount Funds Management LLC (4.02Mn), PERCEPTIVE ADVISORS LLC (3.78Mn), Venrock Adviser, LLC (3.69Mn), Janus Henderson Group Plc (3.31Mn), VANGUARD CAPITAL MANAGEMENT LLC (3.06Mn), DRIEHAUS CAPITAL MANAGEMENT LLC (2.79Mn), State Street Corp (2.61Mn).